CY1119418T1 - Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη - Google Patents

Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Info

Publication number
CY1119418T1
CY1119418T1 CY20171100932T CY171100932T CY1119418T1 CY 1119418 T1 CY1119418 T1 CY 1119418T1 CY 20171100932 T CY20171100932 T CY 20171100932T CY 171100932 T CY171100932 T CY 171100932T CY 1119418 T1 CY1119418 T1 CY 1119418T1
Authority
CY
Cyprus
Prior art keywords
weight loss
compound
compositions
bupropionion
including optional
Prior art date
Application number
CY20171100932T
Other languages
Greek (el)
English (en)
Inventor
Eckard Weber
Michael Alexander Cowley
Original Assignee
Orexigen Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04760321A external-priority patent/EP1617832B1/en
Application filed by Orexigen Therapeutics, Inc. filed Critical Orexigen Therapeutics, Inc.
Publication of CY1119418T1 publication Critical patent/CY1119418T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20171100932T 2003-04-29 2017-09-05 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη CY1119418T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46683803P 2003-04-29 2003-04-29
EP04760321A EP1617832B1 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss
EP07116330A EP1870096A3 (en) 2003-04-29 2004-04-21 Compositions for affecting weight loss

Publications (1)

Publication Number Publication Date
CY1119418T1 true CY1119418T1 (el) 2018-03-07

Family

ID=38719840

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20171100932T CY1119418T1 (el) 2003-04-29 2017-09-05 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη
CY2017041C CY2017041I2 (el) 2003-04-29 2017-12-11 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2017041C CY2017041I2 (el) 2003-04-29 2017-12-11 Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη

Country Status (6)

Country Link
EP (1) EP1870096A3 (enExample)
BE (1) BE2017C064I2 (enExample)
CY (2) CY1119418T1 (enExample)
FR (1) FR17C1058I2 (enExample)
LU (1) LUC00054I2 (enExample)
NL (1) NL300918I2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10576045B2 (en) 2011-02-16 2020-03-03 Nir Barak Low dosage combinations of fluoxetine and reboxetine for treating obesity
CA2899455C (en) 2013-01-30 2021-06-08 Pharmorx Therapeutics, Inc. Treatments for depression and other diseases with a low dose agent

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217353A (en) * 1978-05-19 1980-08-12 E. I. Du Pont De Nemours And Company Method for inducing anorexia
ATE214276T1 (de) * 1994-09-19 2002-03-15 Du Pont Pharm Co Zusammensetzungen von opioid antagonisten mit selektiven serotonin-aufnahme inhibitoren, zur behandlung von alkoholismus und alkohoabhängigkeit
DK0934069T3 (da) * 1996-05-07 2007-03-19 Pliva Istrazivanje I Razvoj D Fremgangsmåde og apparat til behandling af lipid- og glucosemetabolismelidelser
AU2483599A (en) * 1998-01-29 1999-08-16 Sepracor, Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6071918A (en) * 1999-07-21 2000-06-06 Dupont Pharmaceuticals Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1970072A1 (en) * 2000-09-18 2008-09-17 Sanos Bioscience A/S Use of GLP-2 peptides for the treatment of hyperparathyroidism
US20030087896A1 (en) * 2001-08-09 2003-05-08 Hillel Glover Treatment of refractory depression with an opiate antagonist and an antidepressant
US20040102440A1 (en) * 2002-07-01 2004-05-27 Wong Erik Ho Fong Method of promoting smoking cessation
ES2325782T3 (es) * 2002-05-17 2009-09-17 Tioga Pharmaceuticals, Inc. Empleo de compuestos efectivos como moduladores selectivos de receptores de opiaceos.
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake

Also Published As

Publication number Publication date
LUC00054I2 (enExample) 2018-02-21
FR17C1058I1 (enExample) 2018-01-12
EP1870096A2 (en) 2007-12-26
LUC00054I1 (enExample) 2017-12-13
NL300918I2 (nl) 2018-01-09
EP1870096A3 (en) 2011-04-20
BE2017C064I2 (enExample) 2023-08-09
CY2017041I1 (el) 2018-09-05
FR17C1058I2 (fr) 2019-01-11
CY2017041I2 (el) 2018-09-05
NL300918I1 (nl) 2017-12-14

Similar Documents

Publication Publication Date Title
ATE388698T1 (de) Zusammensetzungen zur beeinflussung des gewichtsverlusts
TW200605866A (en) Combination of bupropion and a second compound for affecting weight loss
TR200200118T2 (tr) Yeni bileşimler
ATE496893T1 (de) Isochinolinonderivate und deren verwendung als medikamente
PL374832A1 (pl) Nowe podstawione benzoimidazolowe postacie dawkowe i sposoby ich stosowania
CY1114011T1 (el) Φαρμακευτικη στοματικη δοσολογικη μορφη που περιλαμβανει ενα συνδυασμο ενος οπιοειδους αγωνιστη και ενος οπιοειδους ανταγωνιστη
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
EA200300944A1 (ru) Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина
CY1117217T1 (el) Συνθεση και αντι-ιικη δραστηριοτητα των υποκατεστημενων παραγωγων αζαϊνδολοοξοοξικης πιπεραζινης
NO20074441L (no) 1-benzylindol-2-karboksamidderivater
DK0777666T3 (da) Substituerede piperidiner anvendelige ved behandling af allergiske sygdomme
NO975198D0 (no) Tetralinforbindeler med MDR-aktivitet
DE60303440D1 (de) Benzoxazinonderivate, deren herstellung und deren verwendung als medikamente
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
EA200401584A1 (ru) Способ содействия прекращению курения
CY1119418T1 (el) Συνθεσεις για επηρεασμο απωλειας βαρους που περιλαμβανουν ανταγωνιστη οπιοειδους και μπουπροπιονη
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
CY1110366T1 (el) Ασεναπινη για τη θεραπεια της σχιζοφρενειας σε ενα υπερβαρο ασθενη ή που εχει προδιαθεση να γινει υπερβαρος
CY1106409T1 (el) Παραγωγα κινολινης
DE60027905D1 (de) Glycokonjugate, glycoaminosäure, deren zwischenprodukte, und ihre verwendung
DE602005011450D1 (de) N-(1 h-indolyl)-1 h- indol-2-carboxamid-derivate, deren herstellung und therapeutische verwendung damit
BRPI0409505A (pt) compostos como antagonistas do receptor crf1
DE60011801D1 (de) Benzoxa- und benzthiazolylsulfamate sowie ihre verwendung als steroid-sulfataseinhibitoren
ATE370134T1 (de) 1,4-dithiin und 1,4-dithiepin-1,1,4,4, tetroxid derivate verwendbar als human galanin receptor antagonisten
DE60013703D1 (de) Cycloaliphatische Copolycarbonate, ihre Darstellung und Verwendung